Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma

Next Previous
X
Search
Trial Profile

A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 101 (Primary)
  • Indications Ependymoma; Glioblastoma; Medulloblastoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Mar 2022 Planned End Date changed from 15 Dec 2023 to 17 Nov 2025.
    • 09 Mar 2022 Planned primary completion date changed from 15 Dec 2023 to 17 Nov 2025.
    • 09 Mar 2022 According to a Mustang Bio media release, trial will be presented as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 and abstract will also be published in the online Proceedings of the AACR.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top